NETosis and neutrophil extracellular traps in COVID-19: immunothrombosis and beyond
Y Zhu, X Chen, X Liu - Frontiers in Immunology, 2022 - frontiersin.org
Infection with SARS-CoV-2, the causative agent of the Coronavirus disease 2019 (COVID-
19) pandemic, causes respiratory problems and multifaceted organ dysfunction. A crucial …
19) pandemic, causes respiratory problems and multifaceted organ dysfunction. A crucial …
[HTML][HTML] Severity of COVID-19 in patients with lung cancer: evidence and challenges
A Passaro, C Bestvina, MV Velez… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Cancer patients are highly vulnerable to SARS-CoV-2 infections due to frequent contacts
with the healthcare system, immunocompromised state from cancer or its therapies …
with the healthcare system, immunocompromised state from cancer or its therapies …
[HTML][HTML] Seroconversion rates following COVID-19 vaccination among patients with cancer
As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically
needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we …
needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we …
[HTML][HTML] Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer …
Background Patients with cancer may be at high risk of adverse outcomes from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of …
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of …
[HTML][HTML] Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity,
complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are …
complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are …
[HTML][HTML] Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer
S Ehmsen, A Asmussen, SS Jeppesen, AC Nilsson… - Cancer cell, 2021 - cell.com
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with
cancer: Cancer Cell Skip to Main Content Advertisement Cancer Cell This journal offers …
cancer: Cancer Cell Skip to Main Content Advertisement Cancer Cell This journal offers …
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies
LM Greenberger, LA Saltzman, JW Senefeld… - Cancer cell, 2021 - cell.com
It has been reported that 15%–25% of patients with hematologic malignancies fail to make
anti-spike (anti-S) antibodies in response to full dosing of SARS-CoV-2 mRNA vaccines …
anti-spike (anti-S) antibodies in response to full dosing of SARS-CoV-2 mRNA vaccines …
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX cohort study
PURPOSE The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with
cancer are poorly understood. METHODS We performed a prospective cohort study of adults …
cancer are poorly understood. METHODS We performed a prospective cohort study of adults …
[HTML][HTML] Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been
proven to be highly effective at preventing severe disease and mortality in healthy …
proven to be highly effective at preventing severe disease and mortality in healthy …
COVID-19 and cancer: a review of the registry-based pandemic response
Importance The COVID-19 pandemic has had consequences for patients with cancer
worldwide and has been associated with delays in diagnosis, interruption of treatment and …
worldwide and has been associated with delays in diagnosis, interruption of treatment and …